This recently published paper investigates the effectiveness of a `novel steroid-free cream containing multiple active ingredients’, called Sebclair to treat facial seborrheic dermatitis.
This product sounds quite interesting for rosacea and rosacea/SD sufferers. Little information about Sebclair is currently available on the internet.
Seblair (MAS064D) is approved for use in the European Union to treat seborrheic dermatitis. One of Sebclair’s claim to fame is that it contains no corticosteroids or immunomodulating agents. The paper’s authors admit that it is difficult to know which compound is responsible for Sebclair’s success as a treatment.
The authors state “We believe that the major activity is probably due to the synergistic effect of both piroctone olamine, for its antimycotic action, and glycyrrhetinic acid, for its anti-inflammatory action.”
Sebclair Ingredients
| Ingredient | Concentration | Role |
| Isohexadecane | 8% | Emollient |
| Shea butter | 6% | Emollient |
| Bisabolol | 1.2% | Anti-inflammatory |
| Piroctone olamine | 1% | Antimycotic |
| Alglycera | 1% | Anti-inflammatory and keratolytic |
| Vitamin E | 1% | Anti-inflammatory and antioxidant |
| Allantoin | 0.35% | Keratolytic |
| V. vinifera | 0.1% | Anti-oxidant |
| Telmesteine | 0.01% | Anti-inflammatory and antioxidant |
The following descriptions of each ingredient is supplied in the full text of the paper.
Alglycera is a compound combining the anti-inflammatory properties of glycyrrhetinic acid and the keratolytic properties of allantoin.
Glycyrrhetinic acid, extracted from the licorice root, exhibits anti-inflammatory properties in different organs in several animal models,
with a potency similar to that of indomethacine. Its chemical structure is similar to that of cortisone and has been shown to potentiate the action of hydrocortisone
Piroctone olamine is an antimycotic effective against Malassezia spp.
The standardized extract of V. vinifera (grapevine) in Sebclair contains 40% of epigallocatechin gallate, a proanthocyanidine that prevents oxidative damage to the endothelium, with maintenance of optimal blood supply. It works as an antioxidant synergistically with telmesteine and Vitamin E.
Shea butter, from Butyrospermum parkii, is composed of tryglycerides and fatty acids, including linoleic acid, rich in phytosterols and tocopherols. The action of shea butter is enhanced by isohexedecane, another emollient present in the formulation.
If you live in the EU and suffer from SD, please do let us know how you like Sebclair, but leaving a comment below.
Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial, J Eur Acad Dermatol Venereol. 2008 Mar;22(3):290-6. S Veraldi, A Menter, M Innocenti, Institute of Dermatological Sciences, University of Milan, IRCCS Foundation, Policlinico, Mangiagalli and Regina Elena Hospital, Milan, Italy; Baylor University Medical Centre, Dallas, TX, USA, European Institute of Dermatology, Milan, Italy
Aim: MAS064D (Sebclair) is a novel steroid-free cream containing multiple active ingredients. Objective of this pilot study was to evaluate the efficacy and safety of MAS064D in the treatment of mild to moderate SD of the face.
Methods: Patients (n= 60) with SD were randomized to receive MAS064D (n= 40) or a matching vehicle (n = 20). The primary study endpoint was investigators’ global assessment (IGA) score at day 28, compared with baseline. Secondary endpoints included: IGA score at day 14; investigators’ assessment of erythema and scaling; patients’ assessment of burning/stinging, pruritus and global response to MAS064D; resort to rescue medication; quality of life.
Results: Use of MAS064D for 4 weeks was associated with a higher percentage of success in the MAS064D group than in the vehicle group (~68% vs 11%, P < 0.0001). The effects of MAS064D were significantly better than those of vehicle for investigator-assessed erythema and scaling, and patients’ assessed pruritus and global response to MAS064D (P ≤ 0.01). No patient in the MAS064D
group required rescue medication, compared with two patients in the vehicle group. Four patients (two each in the MAS064D and vehicle groups) reported a total of six non-serious adverse events.
Conclusions: MAS064D appears to be an effective and well tolerated cream for the treatment of mild to moderate SD of the face. Further clinical evaluation of MAS064D in SD is warranted.
Sinclair Pharma: Sebclair
No comments yet ↓
There are no comments yet. Be the first by filling out the form below.
Leave a Comment